RxDoctor Payments Data

Cesar Cardona, MD

Nephrology · Columbia, TNNPI 1578728283

Payments from drug & device makers

$2,291in general payments, 2019–2025

Across 100 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$420
  • Novo Nordisk$281
  • Travere Therapeutics, Inc.$236
  • Boehringer Ingelheim$213
  • AstraZeneca$197
  • Amgen$180
  • plus $765 from 11 others

What the payments were for

  • Food & beverage$2,09191%
  • Education$2009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,291 in reported general payments places this provider in the 60th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$367,916
Medicare patients
905
Services billed
4,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin118$164,262
VelphoroSucroferric Oxyhydroxide38$128,937
KerendiaFinerenone48$72,514
AuryxiaFerric Citrate44$66,791
FarxigaDapagliflozin Propanediol32$39,914
VeltassaPatiromer Calcium Sorbitex15$31,725
Lanthanum Carbonate22$11,755
Sevelamer Carbonate78$8,162
Allopurinol458$4,518
Torsemide97$3,578
Bisoprolol Fumarate144$3,341
Clonidine16$2,739
Furosemide525$2,738
Potassium Chloride89$2,588
Calcitriol95$2,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$213$164,262118 claims
Fresenius USA Marketing, Inc.Velphoro$139$128,93738 claims
BayerKerendia$18$72,51448 claims
Akebia Therapeutics IncAuryxia$78$66,79144 claims
AstraZenecaFarxiga$197$39,91432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Columbia

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →